Skip to main content

Table 1 Summary of results with APR-246 and cisplatin in primary cancer cells from the patients

From: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

Ascites sample Diagnosis Histological description Prior chemo-therapy Platinum sensitivity IC50 APR-246 (μM) IC50 cisplatin (μM) p53 status p53 protein levels Combination APR-246 cisplatin
1 Ovarian cancer stage III Poorly differentiated serous carcinomaa Yes Resistant 25 40* R280K (hom.) ++ SS
2 Cancer peritonei stage IV Serous carcinoma Yes Resistant 24 18 wt S, Add
3 Ovarian cancer stage IC Serous carcinoma Yes Resistant 37 32 L111Q (het.) + S, SS
4 Ovarian cancer/Cancer peritonei stage IV Poorly differentiated serous carcinomaa Yes Resistant 18 3.2 P151H (het.) + SS
5 Cancer peritonei stage IIIC Serous adenocarcinoma, grade IIIa No Sensitive 22 16 C135Y (hom.) + SS
6 Tubar cancer stage IIIB Poorly differentiated serous adenocarcinomaa Yes Sensitive 12 17 C238F (het.) ++ SS
7 Ovarian cancer stage IIIC Poorly differentiated serous carcinomaa Yes Resistant 56d 45d E346* (het.) S, Add
8 Cancer Peritonei stage IV Poorly differentiated serous carcinomaa No Sensitive 8.9 7.1 E204* (hom.) SS
9 Ovarian cancer stage IIIC Poorly differentiated serous carcinomaa Yes Resistant 5.2 7.9 P278R (hom.) + SS
10 Ovarian cancer stage IIIC Medium-well differentiated serous adenocarcinomaa,b Yes Sensitive 8.0 17 Y163H (het.) + SS
  1. Cell viability was assessed by the FMCA assay. Combination Index (CI) was calculated using the Additive model.
  2. Diagnosis: The 10 samples included in the study were from patients diagnosed with ovarian, peritoneal, or fallopian tube cancer. Strong data suggest that high-grade serous (HGS) carcinomas found in these tissues share a similar origin and pathogenesis pointing out the distal part of the fallopian tubes as the origin in the majority of cases [2, 3].
  3. Histological description: The primary histopathological analysis of the samples in this study was performed using the previous grading system and heterogeneous criteria and not according to the present standard where tumors are classified into low- and high-grade serous carcinomas.
  4. aThese samples are classified as HGS carcinoma according to the current criteria [16]. Likely is also sample 3 with TP53 mutation HGS carcinoma.
  5. bPatient 10 was later reoperated for distant metastasis and the histopathological analysis showed HGS tumor.
  6. Platinum sensitivity: patients who relapse > 6 months are classified as platinum-sensitive; patient who relapse < 6 months are platinum-resistant.
  7. p53 status: het. = heterozygous; hom. = homozygous; * = stop codon. The sequencing method used cannot distinguish homozygous from hemizygous mutations, neither can heterozygosity be distinguished from a mixture of cells with wild type and mutant TP53.
  8. p53 protein levels:− = not detected; + = medium; ++ = high.
  9. Combination APR-246 cisplatin: Add = additive effect (CI = 1.0 ± 0.2); S = synergy (CI < 0.8); SS = strong synergy (CI < 0.5).
  10. cThe dose-response curve of cisplatin levelled off and thus resulted in difficulty to determine the IC50 value.
  11. dCisplatin and APR-246 had high IC50 values in sample 7. Moreover, results from combination experiments in this sample were variable resulting in high standard error.